World Tuberculosis Day 2013 TB situation in 2011: Findings from the ECDC and WHO/EURO joint TB surveillance report ECDC TB Team European Centre for Disease.

Slides:



Advertisements
Similar presentations
Números.
Advertisements

Capítulo Preliminar Los Números.
Un percorso realizzato da Mario Malizia
AGVISE Laboratories %Zone or Grid Samples – Northwood laboratory
SOTS OCTOBER 21-23, 2009 CONCURRENT RETIREMENT AND DISABILITY PAYMENTS (CRDP)
Fill in missing numbers or operations
Worksheets.
Ozone Level ppb (parts per billion)
Addition and Subtraction Equations
Multiplication X 1 1 x 1 = 1 2 x 1 = 2 3 x 1 = 3 4 x 1 = 4 5 x 1 = 5 6 x 1 = 6 7 x 1 = 7 8 x 1 = 8 9 x 1 = 9 10 x 1 = x 1 = x 1 = 12 X 2 1.
Division ÷ 1 1 ÷ 1 = 1 2 ÷ 1 = 2 3 ÷ 1 = 3 4 ÷ 1 = 4 5 ÷ 1 = 5 6 ÷ 1 = 6 7 ÷ 1 = 7 8 ÷ 1 = 8 9 ÷ 1 = 9 10 ÷ 1 = ÷ 1 = ÷ 1 = 12 ÷ 2 2 ÷ 2 =
How many people do we need to vaccinate?. Suppose R 0 = 10 How many new infections result from each infected person on average? 10 So how many people.
CALENDAR.
1 1  1 =.
1  1 =.
Partial Products for Multiplication
Year 6 mental test 10 second questions Numbers and number system Numbers and the number system, fractions, decimals, proportion & probability.
The challenge of harnessing the demographic dividend
Centre for Adolescent Health Global patterns of mortality in young men & women Professor George Patton. Expert Group Meeting on Adolescents, Youth & Development,
突破信息检索壁垒 -SciFinder Scholar 介绍
Responses to infectious diseases among people who inject drugs: Policies and measures taken in Europe Dagmar Hedrich, EMCDDA Project Imp.Ac:T - Improving.
The basics for simulations
Look at This PowerPoint for help on you times tables
Claire OShea, Podiatrist (Presenting on behalf of the Waikato Regional Diabetes Service, Multi-disciplinary foot team, Vickie Corbett CNS Diabetes, Leigh.
TCCI Barometer March “Establishing a reliable tool for monitoring the financial, business and social activity in the Prefecture of Thessaloniki”
TCCI Barometer March “Establishing a reliable tool for monitoring the financial, business and social activity in the Prefecture of Thessaloniki”
What if you knew exactly what kids need to succeed? What if you knew exactly what kids need to succeed?
Implementation of new secondary grading scales in Infinite Campus Current U-46 Scales A 89-80B 79-70C 69-60D 59-0E ‘13-’14: Scale A.
Progressive Aerobic Cardiovascular Endurance Run
Least Common Multiples and Greatest Common Factors
TCCI Barometer September “Establishing a reliable tool for monitoring the financial, business and social activity in the Prefecture of Thessaloniki”
Partial Products Algorithm for Multiplication Created by Rina Iati South Western School District Hanover, PA.
Country Update: Tuberculosis in Thailand
2011 WINNISQUAM COMMUNITY SURVEY YOUTH RISK BEHAVIOR GRADES 9-12 STUDENTS=1021.
The TB situation in the Americas: Reaching the MDGs on TB Dr. Jarbas Barbosa Area Manager, Health Surveillance & Disease Management 23 March 2007.
Before Between After.
Benjamin Banneker Charter Academy of Technology Making AYP Benjamin Banneker Charter Academy of Technology Making AYP.
2011 FRANKLIN COMMUNITY SURVEY YOUTH RISK BEHAVIOR GRADES 9-12 STUDENTS=332.
Subtraction: Adding UP
The Global Village The world is a crowded place. As of today the world’s population is 6,600,000, countries have more that 50 million people. 11.
Static Equilibrium; Elasticity and Fracture
Resistência dos Materiais, 5ª ed.
Fourth Quarter Oklahoma Data (October-December 2011)
Biostatistics course Part 14 Analysis of binary paired data
2013 HIV/AIDS Surveillance in Europe European Centre for Disease Prevention and Control, Stockholm WHO Regional Office for Europe, Copenhagen.
Chart Deception Main Source: How to Lie with Charts, by Gerald E. Jones Dr. Michael R. Hyman, NMSU.
Schutzvermerk nach DIN 34 beachten 05/04/15 Seite 1 Training EPAM and CANopen Basic Solution: Password * * Level 1 Level 2 * Level 3 Password2 IP-Adr.
M. Samarkos TUBERCULOSIS IN GREECE. INTRODUCTION.
World Tuberculosis Day 2015 The TB situation in 2013: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
World Tuberculosis Day 2014 The TB situation in 2012: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
World Tuberculosis Day 2014 The TB situation in 2012: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
Three key messages on tuberculosis control World Tuberculosis Day 2010 ECDC TB Team European Centre for Disease Prevention and Control Stockholm, 24 March.
Table 1. Numbers and rates of TB cases per population by country and year, EU/EEA, 2010–2014 ASR: age-standardised rate, C: case-based Source:
World Tuberculosis Day 2016 Monitoring the implementation of the Framework Action Plan to Fight Tuberculosis in the European Union – Situation in 2014.
Figure 1. Weekly proportion of sentinel specimens positive for influenza virus and number of detections by type and subtype, EU/EEA, 2014–2015 Suggested.
World Tuberculosis Day 2014
World Tuberculosis Day 2013
World Tuberculosis Day 2014
World Tuberculosis Day 2015
Tuberculosis situation in the EU/EEA, 2016
World Tuberculosis Day 2014
World Tuberculosis Day 2016
World Tuberculosis Day 2014
Source: Country reports
Tuberculosis situation in the EU/EEA, 2017
Table 1. Table 1. Reported confirmed toxoplasmosis cases: number and rate per live births, EU/EEA, 2010–2014 Source: Country reports. Legend: Y.
Tuberculosis situation in the EU/EEA, 2017
Tuberculosis situation in the EU/EEA, 2017
Table 1. Reported confirmed yersiniosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N =
Presentation transcript:

World Tuberculosis Day 2013 TB situation in 2011: Findings from the ECDC and WHO/EURO joint TB surveillance report ECDC TB Team European Centre for Disease Prevention and Control Stockholm, 24 March 2013

TB notification rates in EU/EEA, 2011 In the EU/EEA, TB cases were reported in Notification rate 14.2 per population (range 2.8 – 89.7). 2 Not included or not reporting 50 to 99 per to 49 per to 19 per < 10 per Figure 1: Country-specific TB notification rates, 2011

TB notification rates in EU/EEA, 2007−2011 Overall in the EU/EEA, notification rates have steadily declined. 3 Figure 2: Trend in TB notification rate in the EU/EEA 2007−2011

Proportion of confirmed* TB cases in the EU/EEA, 2011 Overall 61.3% (range 27.9 – 94.8%) of TB cases reported in the EU/EEA were laboratory-confirmed. 4 Figure 3: Country-specific proportion of all confirmed TB cases in to 79% ≥ 80% 60 to 69% < 60% Not included or not reporting *Confirmed by culture or both a positive sputum microscopy result and Mycobacterium tuberculosis nucleic acid identified in nucleic acid amplification test.

TB notification rates in children <15 years of age in EU/EEA, 2011 In 2011, cases of TB in children were reported, accounting for 4.4% of all notified TB cases (range 0 – 11.1%) in the EU/EEA. 5 Figure 4: Country-specific childhood TB notification rates among child population (0–14 years), 2011 Not included or not reporting 4 to 9.9 per child population 2 to 3.9 per child population ≥ 10 per child population < 2 per child population

Proportion of foreign origin among notified TB cases in EU/EEA, In 2011, the overall proportion of TB cases of foreign origin in the EU/EEA was 25.8% (range 0.3 – 89.4%). Figure 5: Country-specific proportion of foreign origin cases among all notified TB cases, EU/EEA, to 49% ≥ 75% 1 to 24% 50 to 74% < 1% Not included or not reporting

Proportion of notified extrapulmonary TB cases in EU/EEA, In 2011, the overall proportion of extrapulmonary TB cases in the EU/EEA was 22.3% (range 3.9 – 66.7%). Figure 6: Country-specific proportion of extrapulmonary TB of all notified TB cases, EU/EEA, to 29% ≥ 50% 5 to 19% 30 to 49% < 5% Not included or not reporting

Extrapulmonary TB notification rates in EU/EEA, 2002−2011 Extrapulmonary TB notification rates have remained stable in the last 10 years. 8 Figure 7: Trend in extrapulmonary TB notification rate in the EU/EEA, 2002−2011

Proportions of TB by site among all notified TB cases in EU/EEA, 2002−2011 Percentage of extrapulmonary TB increased from 16.4% in 2002 to 22.4% in Figure 8: Proportion of notified pulmonary and extrapulmonary TB cases in the EU/EEA, 2002−2011

Proportion of culture-confirmed new pulmonary TB cases in EU/EEA, % of new pulmonary TB cases were culture-confirmed. The proportion varied widely across countries (range 0 – 98%). 10 Figure 9: Proportion of new pulmonary TB cases confirmed by culture, 2011

Proportion of notified TB cases with multi-drug resistance among all confirmed TB cases in EU/EEA, In 2011, the overall proportion of TB cases with multi-drug resistance in the EU/EEA was 4.5% (range 0 – 29.8%). Figure 10: Country-specific proportion of multidrug resistance among all confirmed TB cases, EU/EEA, to 4.9% ≥ 10% 1 to 1.9% 5 to 9.9% < 1% Not included or not reporting

Proportion of notified new TB cases with multidrug resistance in EU/EEA, In 2011, the overall proportion of new TB cases with multi- drug resistance in the EU/EEA was 2.4% (range 0 – 23.3%). Figure 11: Country-specific proportion of new TB cases with multidrug resistance, EU/EEA, to 4.9% ≥ 10% 1 to 1.9% 5 to 9.9% < 1% Not included or not reporting

Notification rates of new cases with multidrug resistant TB in EU/EEA, 2007−2011 The notification rate of multidrug resistant TB have remained stable at around 0.3 per population. 13 Figure 12: Trends in multidrug resistant TB notification rate in the EU/EEA, 2007−2011

Proportion of notified previously treated TB cases with multidrug resistance in EU/EEA, In 2011, the overall proportion of previously treated TB cases with multidrug resistance in the EU/EEA was 16.8% (range 0 – 57.7%). Figure 13: Country-specific proportion of previously treated TB cases with multi-drug resistance, EU/EEA, to 4.9% ≥ 10% 1 to 1.9% 5 to 9.9% < 1% Not included or not reporting

Proportion of TB cases with extensive drug resistance among MDR-TB cases with SLD ST* reported in EU/EEA, In 2011, the proportion of extensive drug resistant cases among cases with multidrug resistance in EU/EEA was 13.4% (range 0 – 40.0%). Figure 14: Country-specific proportion of extensively drug resistant TB cases among TB cases with multi-drug resistance, EU/EEA, to 9% ≥ 20% 1 to 4% 10 to 19% < 1% *SLD ST – second line drug susceptibility testing result Not included or not reporting

Proportion of HIV positive TB cases among all TB cases with known HIV status in EU/EEA, In 2011, the overall proportion of HIV positive TB cases among TB cases with known HIV status in EU/EEA was 4.7% (range 0 – 40%). Figure 15: Country-specific proportion of HIV positive TB cases among TB cases with known HIV status, EU/EEA, to 4.9% ≥ 10% 1 to 1.9% 5 to 9.9% < 1% Not included or not reporting

Treatment success rate for new pulmonary TB cases in EU/EEA*, 2010 The treatment success rate for new culture-confirmed pulmonary TB cases notified in 2010 was 76.8% (range: 0 – 91.4%). 17 Figure 16: Treatment success rate for new culture-confirmed pulmonary TB cases notified in 2010 * Five EU/EEA Member States did not report treatment outcome data.

Treatment success rate for new pulmonary TB cases by year of reporting in EU/EEA, 2006−2010 The treatment success rate for new culture-confirmed pulmonary TB cases notified between 2006 and 2010 has slightly decreased from 79.5% in 2006 to 76.8% in Figure 17: Treatment success rate for new culture-confirmed pulmonary TB cases notified in 2006−2010

Treatment success rate for previously treated pulmonary TB cases in EU/EEA*, 2010 The treatment success rate for previously treated culture-confirmed pulmonary TB cases notified in 2010 was 53.7% (range 31.4 – 85.7%). 19 Figure 18: Treatment success rate for previously treated culture-confirmed pulmonary TB cases notified in 2010 * Iceland and Luxembourg reported zero previously treated TB cases in Seven EU/EEA Member States did not report stratified treatment outcome data

Treatment success rate for all notified pulmonary TB cases in EU/EEA*, 2010 The treatment success rate for all confirmed pulmonary TB cases notified in 2010 was 72.4% (range 0 – 88.9%). 20 Figure 19: Treatment success rate for all confirmed pulmonary TB cases notified in 2010 * Five EU/EEA Member States did not report treatment outcome data

Treatment success* rate for extrapulmonary TB cases in EU/EEA**, 2010 The treatment success rate for extrapulmonary TB cases notified in 2010 was 82.2% (range 21.1 – 100%). 21 Figure 20: Treatment success rate for extrapulmonary TB cases notified in 2010 *Treatment success of extrapulmonary TB consists of cases reported as completed full course of anti-tuberculosis treatment ** Seven Member States did not report stratified treatment outcome data

Treatment success rate for notified multidrug-resistant TB cases in EU/EEA*, 2009 The treatment success rate for all confirmed multidrug-resistant TB cases notified in 2009 was 31.6% (range 0 – 84.6%). 22 Figure 21: Treatment success rate for all confirmed multidrug-resistant TB cases notified in 2009 * Malta reported zero MDR TB cases in 2009, 11 Member States did not report treatment outcome data

Treatment outcome for multidrug-resistant TB cases notified in 2007−2009 Treatment outcomes for multidrug-resistant TB cases did not improve between the 2007 and 2009 cohort, EU/EEA. 23 Figure 22: Treatment outcome at 24 months for multidrug-resistant TB cases diagnosed in 2009, compared with cases diagnosed in 2007 and 2008